SUDO-550, an oral therapy for MS, was found to be safe and to reach the brain in its first human clinical trial, trial ...

Video content above is prompted by the following: The multiple sclerosis (MS) treatment landscape has dramatically evolved from just 4 interferon-based agents in 2010 to over 22 disease-modifying ...

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...

Kesimpta is a medication used to treat relapsing forms of multiple sclerosis (MS) and clinically isolated syndrome (CIS). Kesimpta comes as a solution inside single-dose prefilled injection pens or ...

Considering the CLARITY Phase III study results, cladribine tablets may offer several improvements over existing MS drugs including a simple, short-course annual dosing regimen of either 2 or 4 weeks ...

The chronic progressive multiple sclerosis market size is anticipated to grow during the forecast period (2025–2034). According to DelveInsight's ...

Two key symptoms that can arise soon after a diagnosis of multiple sclerosis (MS) could predict how swiftly the illness will progress and suggest best treatment options, new research shows. The two ...

A mum with multiple sclerosis has become the first patient in the UK to receive an experimental treatment that could slow or even stop progression of the disease.

Cabaletta Bio, Inc. (($CABA)) announced an update on their ongoing clinical study. RESET-MS is a Phase 1/2 open-label study conducted by Cabaletta ...

Many women develop multiple sclerosis (MS) during their reproductive years. Since MS treatment can affect pregnancy, understanding your birth control options can make family planning easier. Research ...